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BACKGROUND 
Gastric acid suppressants increase the risk of gastroenteritis by allowing ingested pathogens to 
survive passage through the stomach.  It is not known whether the same mechanism affects 
transmission of Enterobacteriacae.  We carried out a case-control  study to answer this question. 
AIM 
To determine whether use of Proton Pump Inhibitors (PPIs) increases the risk of infection with 
Enterobacteriacae in hospital patients.  
METHODS 
Retrospective case-control study in a teaching hospital in South West England. Cases were 126 
patients infected with extended-spectrum Lactamase producing Enterobacteriacae (ESBL ) 
between April 2014 and March 2015.  Use of PPIs, H2 receptor antagonists or antacids at the time of 
admission or in the preceding six months was compared with 126 demographically matched controls 
infected with non-ESBL producing Enterobacteriacae and 126 uninfected controls, matched by 
primary diagnosis.  
FINDINGS   
66 of 126 ESBL cases, 62 of 126 non-ESBL controls and 34 of 126 uninfected controls were prescribed 
PPIs on or within 6 months of admission.  Multivariable logistic regression analysis gave an Odds 
Ratio (95% confidence interval) of 3.37 (1.84 - 6.18) for PPI exposure versus uninfected controls and 
1.15 (0.68 - 1.95) for ESBL infection versus non-ESBL infection.  H2RA and antacids were not 
significantly associated with infection. 
CONCLUSION 
PPI exposure within the previous 6 months is significantly associated with infection with both ESBL 
and non-ESBL producing bacteria.  Reducing inappropriate use of PPIs may be a novel way of 
reducing transmission, which might reduce antibiotic use and help control antimicrobial resistance. 
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INTRODUCTION 
Antibiotic resistance in Gram-negative bacteria is a major global cause of morbidity and mortality 
[1].  It has been identified as an urgent priority by the WHO, EU and US and UK Governments [2-5]. 
PPI use reduces gastric acidity, alters the gut microbiome [6], and increases the risk of gastroenteritis 
by enabling ingested pathogens to survive passage through the stomach [7].  The protective effect of 
gastric acid is unrelated to antibiotic resistance, so it is possible that PPI use might encourage 
colonisation by resistant or sensitive bacteria, with subsequent risk of systemic infection?  Very little 
research has been carried out to investigate this, particularly in UK hospital patients.   
We carried out a retrospective case-control study of PPI exposure in hospital cases infected with 
extended-spectrum -lactamase producing Enterobacteriacae (ESBL ) compared with two 
demographically matched control groups.  The first group were patients infected with extended-
Spectrum -lactamase negative Enterobacteriacae (non-ESBL) and the second group were patients 
with no identified enterobacteriaceal infection matched by primary diagnosis (uninfected). 
 
METHODS 
STUDY COHORT 
This study was carried out in Derriford Hospital, a 1000 bed university teaching hospital in South 
West England.  All 131 patients newly identified as infected with ESBL between 1st April 2014 and 
31st March 2015 (cases) were identified from laboratory records.  This included inpatients and 
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patients undergoing day-case procedures.   Five patients were excluded as their casenotes were lost 
and no information was available in electronic records.  No screening of asymptomatic patients was 
performed, all samples were routine diagnostic tests.  Controls were selected from the same 
hospital population infected with non-ESBL producing Enterobacteriacae matched by age +/-  three 
years, date of admission +/- three months, gender, Care Group (Medicine, Surgery, Tertiary Services 
or Women & Children) and origin (Home, Other Hospital).  A second set of controls with the same 
demographic features and also matched by their primary non-infectious diagnosis was similarly 
selected.   Once a set of eligible controls was identified, one control per case was randomly selected 
using the Globally Unique Identifier (GUID) function in Microsoft SQL.  No eligible controls could be 
found for 14 cases, either because of extreme age or uncommon primary diagnosis.  Both genders 
were permitted and age matching was relaxed to +/- five years for these cases.   A power calculation 
prior to data collection indicated that this sample size would be adequate to detect an odds ratio of 
2.1 with 80% power at a 5% level of significance.   
Clinical data was extracted from paper and electronic hospital casenotes, post-discharge coding 
records and electronic discharge summaries.  The study was approved by the North West Medical 
Research Ethics Committee and the Plymouth Hospitals NHS Trust Research and Development 
Office. 
EXPOSURES 
Documented prescription of PPI, H2RA or simple antacids on admission or during previous episodes 
of care in the preceding six months was recorded.  Over the counter use of gastric acid suppressants 
was not reliably recorded and was not analysed. 
CONFOUNDING VARIABLES 
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A wide range of co-morbidities including those included in the Charlson Co-morbidity Score were 
analysed.  Duration of admission prior to positive bacterial culture was recorded.  Foreign travel 
prior to admission was not reliably recorded and was not analysed. 
STATISTICAL ANALYSIS  
Demographic characteristics of the cases and controls were presented using descriptive statistics. 
Continuous variables such as age and Charlson co-morbidity index were categorized into groups for 
the purpose of comparison with existing literature. Conditional logistic regression model was used to 
investigate the relationship between an outcome of being infected with extended-spectrum β-
lactamase (ESBL) positive and a set of prognostic factors such as exposure to PPI, H2RA, antacids and 
Charlson co-morbidity index. This was done for each of the control groups. Both univariable 
(adjusted for the matching variables) and multivariable logistic regression models were considered 
and the corresponding results presented. Possible interaction of the factors (such as PPI) with some 
of the matching variables (such as age) was tested by including an interaction term in the model. 
Results of the regression models were presented as odds ratio (OR) along with their 95% confidence 
intervals (CIs).  A factor was considered statistically significant if the 95% CI of the corresponding OR 
did not contain 1.  Whenever appropriate, a 5% level of significance was considered. Data analysis 
was performed using IBM SPSS Statistics 23 and STATA 14.  
 
PATIENT INVOLVEMENT 
No patients were involved in the design or implementation of the study, or writing up of results. 
RESULTS 
Characteristics of case and control patients are summarised in Table I.  The median (IQR) time 
between admission and sample collection was 2 (11.3) days for ESBL cases and 1 (5.5) days for non-
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ESBL controls.  This suggests that colonisation occurred prior to admission in most cases, rather than 
being hospital acquired.  The median (IQR) duration of admission of uninfected controls was shorter 
than either of the infected groups at two (11) days versus 12 (20) days for cases and 9 (16) days for 
non-ESBL controls. The Charlson co-morbidity score for cases ranged from 0 to 12 and that of 
controls ranged from 0 to 14.  This was not significantly different between cases and controls.  
The results of exposure to gastric acid suppressants are summarised in Table II.  66 ESBL cases (59 on 
admission and 7 in the previous six months) were exposed to PPIs, compared with 34 (31 on 
admission, 3 in the previous six months) of the uninfected controls and 62 (55 on admission, 7 in the 
previous 6 months) of the non-ESBL controls.  After multivariable analysis the OR (95% CI) for PPI 
exposure in cases compared to uninfected controls was found to be 3.37 (1.84 to 6.18).  No 
significant difference was found for PPI exposure in ESBL cases and non ESBL controls. 
6 ESBL cases were taking H2RA on admission, compared with 9 of the uninfected controls and 7 of 
the non-ESBL controls.  4 ESBL cases were taking antacids on admission, compared with 2 of the 
uninfected controls and 3 of the non-ESBL controls.   No significant association was found between 
cases and either control group for H2RA or antacids.  
 
DISCUSSION 
We found that exposure to PPIs is a significant risk factor for infection with both ESBL producing and 
non-ESBL producing Enterobacteriacae.  This is a novel and important finding, as PPIs are widely 
overused, antibiotic resistance is a major threat, and conventional control measures will require an 
unprecedented level of global cooperation [8, 9].  Increased transmission of susceptible organisms 
following reduction in gastric acidity is just as important as the effect on resistant ones, as treatment 
of subsequent infections will increase antibiotic consumption and drive development of resistance.  
New antibiotic classes are unlikely to be a realistic solution.  Resistance to these may already exist, 
as bacteria from ancient soil and mummified human remains contained genes coding for resistance 
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thousands of years before antibiotics were developed[10,11]. Global spread of resistance is 
inevitable, carried by healthy travellers [12], and in foods from endemic areas [13].  
Gram-positive pathogens like meticillin-resistant Staphylococcus aureus are mainly spread by direct 
contact and are controllable with simple measures like hand washing and skin disinfection.  Most 
transmission of Gram-negative bacteria is by ingestion, and bowel decolonisation is rarely successful.   
They cause no symptoms when they first colonise the bowel.  Unless the patient is actively screened 
they remain undetected until infection occurs in the future [14].    
Gastric acid is a vital host defence.  It kills a wide range of bacteria, fungi and parasites.  It acts 
synergistically with salivary nitrite, generating highly reactive nitrogen species at low pH.  These are 
rapidly bactericidal, even killing acid tolerant organisms such as Clostridium difficile spores [15].  
Gastric acidity is reduced in the elderly, patients with pernicious anaemia, and patients taking PPIs.  
The risk of infection with gastrointestinal pathogens is increased in all these groups [7], our results 
suggest that the same mechanism encourages transmission of Enterobacteriacae. 
PPIs are vital for treating peptic ulcers, gastroesophageal reflux and other serious conditions 
exacerbated by gastric acidity.  Rapid efficacy and the misperception that they are free of significant 
adverse effects has encouraged overuse.  Studies show that 40%-60% of acute hospital inpatients 
are prescribed a PPI, often outside evidence-based guidelines [16,17].  In contrast to the complex 
strategies to control antimicrobial resistance recommended in the O’Neill report [8], reducing 
inappropriate PPI use is a simple intervention which can be initiated by any prescriber or 
empowered patient.  Like hand washing between patient contacts, it is simply good practice, but 
could have a disproportionate impact on the spread of bacterial resistance? 
Strengths and limitations of study 
The hypothesis that PPI use might be associated with ESBL infection was generated before collection 
or analysis of the data.  When a positive association was found, a second control group of patients 
infected with non-ESBL bacteria was analysed.  This study included 126 of 131 new cases of ESBL 
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infection over one year at a large UK teaching hospital.  Derriford hospital provides general medical, 
surgical and obstetric care to an urban and rural population of 450,000, and specialist services such 
as neurosurgery, cardiothoracic surgery, bone marrow and solid organ transplantation to 1.7 million 
people.  This varied case mix gives reassurance that the results are generalizable to similar centres.  
Patients of all ages and from all specialties were included.  We reviewed all available records, 
including casenotes, prescription charts and electronic records.   Limitations of the study are that it is 
retrospective and single centre.   We were unable to quantify any “over the counter” use of gastric 
acid suppressants; however PPIs were only available on prescription at the time so would not have 
affected our cohort.   While every effort was made to match cases and controls, unrecognised co-
morbidities may have been present.  Finally we chose six months prior to admission as a pragmatic 
cut off for review of prescriptions.   PPI use more than six months prior to admission may well be a 
risk factor for acquisition of Enterobacteriacae, and further studies reviewing GP records for lifetime 
PPI use would more accurately define the risk. 
Comparison with other studies 
There is little published research on whether PPIs could be a risk factor for acquisition of 
Enterobacteriacae.   A study in mice found that PPI treatment facilitated colonisation with Klebsiella 
pneumoniae and vancomycin-resistant enterococci  [18]. Two studies of inpatients in Israel and the 
US incidentally found an association between gastric acid suppression and resistant 
Enterobacteriacae, but they primarily focussed on other risk factors and did not comment 
specifically on PPIs [19,20].  A cross-sectional study of adults registered with the Academic General 
Practice Network in Amsterdam in 2011 found an 8.6% prevalence of ESBL-producing 
enterobacteriaceae.  Travel outside Europe, antibiotic use and use of gastric acid suppressants were 
all positively associated with carriage.  Use of PPIs or H2RA had a multivariable odds ratio of 1.9 
(95% CI 1.1 - 3.3) [21].   Our study found a stronger association, perhaps because the hospital 
population has more comorbidity and is more intensively exposed to bacteria and antibiotics.  A 
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cross-sectional study of patients routinely screened for ESBL producing Enterobacteriacae on 
admission to hospital in the Netherlands found that 8.5% of PPI users were carriers versus 2.9% of 
non-PPI users, (adjusted odds ratio 3.89, 95% CI 1.65 - 9.19). Patients were screened within two days 
of admission thus excluding cross-infection within hospital, however they did not control for 
diagnosis or co-morbidities [22].  Søgaard et al in Denmark published a case-control study of 
community-onset ESBL E.coli UTI compared with non-ESBL E.coli UTI and population controls.  They 
found a moderately increased risk of ESBL versus non-ESBL infection (OR 1.6, 95% CI 1.2 - 2.0) and 
that most risk factors also applied for non-ESBL infection  [23]. Finally, two studies have looked at 
the possible association between carbapenemase-producing Enterobacteriacae (CPE) and PPIs, with 
conflicting results.  Weekly screening of 31,526 inpatients in Hong Kong found that concomitant use 
of antibiotics and PPIs prolonged the duration of CPE carriage [24].  A study of 747 inpatients in 
Manchester was conducted during a CPE outbreak, with 70 CPE carriers identified.  PPIs were not 
identified as a risk factor in this cohort, though they used PPI prescription in the 24 hours before the 
case finding exercise as a proxy measure of exposure.  This would have underestimated any effect of 
previous PPI use [25]. 
Clinical implications and future research 
We found that PPIs are much more widely used than H2RA and antacids.   Studies on gastroenteritis 
pathogens show a dose-response effect, with less potent agents conferring a lower risk.  While the 
number of patients taking H2RA and antacids in our population was small, we did not detect any 
association with ESBL or non-ESBL infection.  Future studies to confirm this would be useful, as 
substituting these for PPIs may be easier than stopping gastric acid suppression completely.   
As part of a bundle of C.difficile control measures, the Pharmacy and Infection Prevention and 
Control teams in Derriford Hospital encouraged substitution of H2RA and antacids for PPIs where 
possible.  The initiative included an educational campaign for prescribers and prescription review by 
ward pharmacists.  PPI use reduced from 46% to 29% of inpatients between 2012 and 2016. This 
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confirms that many PPI prescriptions are unnecessary and that change can be effected using existing 
teams and resources.  Electronic prescribing and automated alert systems have also been used to 
reduce co-administration of PPIs and antibiotics [26].  Reducing inappropriate use of any medicine is 
intrinsically worthwhile, but further research is required to determine whether this will have a 
positive impact on transmission of Enterobacteriacae. 
If this is a causal association, there are significant implications for policymakers and clinicians 
managing common gastrointestinal disorders.  PPIs are widely overprescribed in primary and 
secondary care.  Heavily promoted by the pharmaceutical industry, they have replaced H2 receptor 
antagonists as the treatment of choice for dyspepsia, and are now available over the counter.  The 
association between PPI use and C.difficile infection was first described in 2003 but it was not until 
2012 that sufficient evidence accumulated to enable the FDA to mandate a warning on PPI 
datasheets.  As antibiotic resistance is such a serious issue and PPIs are so widely overused, we 
suggest a similar FDA warning should be urgently considered if further research confirms our 
findings.   
 
CONCLUSIONS 
We found a significant association between PPI exposure and infection with both ESBL and non-ESBL 
producing Enterobacteriacae.  This is the first time this risk factor has been identified in a UK hospital 
population and the magnitude is greater than in previous community based studies. Applying 
evidence based guidelines on appropriate use of PPIs has the potential to reduce bacterial 
transmission without harming those patients who genuinely need such potent gastric acid 
suppression.      
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Table 
Baseline characteristics and outcomes for cases and matched controls. Values are numbers 
(percentages) unless stated otherwise.  
Characteristics  ESBL Cases  Non-ESBL Controls  
 
Uninfected Controls  
Total  126 126 126 
Mean (SD) age, years 70 (17.8)  71 (17.7) 70 (17.7) 
Female sex 79 (62.7) 78 (61.9) 84 (66.7) 
Care Group    
- Medical  75 (59.5) 74 (58.7) 74 (58.7) 
- Surgical  28 (22.2) 31 (24.6) 29 (23) 
- Tertiary Services  22 (17.5) 20 (15.9) 22 (17.5) 
- Women and Children 1 (0.8) 1 (0.8) 1 (0.8) 
Origin 
- Home  
- Other hospital 
 
120 (95.2) 
6 (4.8) 
 
123 (97.6) 
3 (2.4) 
 
120 (95.2) 
6 (4.8) 
Length of stay in days 
Median (IQR) 
12 (20)  9 (16) 2 (11) 
16 
 
Days from admission to 
sample collection 
Median (IQR)  
2 (11.25)  
 
1 (5.5)  N/A 
Exposed to PPI 66 (52.4) 62 (49.2) 34 (27) 
Exposed to H2RA 6 (4.8) 7 (5.6) 9 (7.1) 
Exposed to Antacids 4 (3.2) 3 (2.4) 2 (1.6) 
Charlson Score 
- 0 
- 1-2 
- ≥3 
 
31 (24.6) 
41 (32.5) 
54 (42.9) 
 
34 (27) 
50 (39.7) 
42 (33.3) 
 
31 (24.6) 
30 (23.8) 
65 (51.6) 
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Table II 
Odds ratio (95% confidence interval) of risk factors for infection with extended-spectrum β-
lactamase  (ESBL) producers versus two sets of controls (uninfected and non-ESBL producers) based 
on univariable and multivariable logistic regression models                            
 
Characteristic 
ESBL cases versus uninfected controls ESBL cases versus non-ESBL controls 
Univariable Multivariable Univariable Multivariable 
Exposed to PPI 2.88 (1.66- 5.00) 3.37 (1.84 - 6.18) 1.15 (0.68 - 1.95) 1.06 (0.62 - 1.82) 
Exposed to H2RA 0.57 (0.17 to 1.95) 0.92 (0.24 - 3.57) 0.8 (0.21 - 2.98) 0.68 (0.18 - 2.67) 
Exposed to 
Antacids  
2.00 (0.37 -  10.92) 0.98 (0.16 - 6.06) 1.33 (0.30 - 5.96) 1.57 (0.34 - 7.29) 
Charlson score* 
    Medium vs low 
    High vs low 
 
1.26 (0.65 - 2.46) 
0.82 (0.43 - 1.57) 
 
1.16 (0.56 - 2.39) 
0.58 (0.28 - 1.20) 
 
0.90 (0.44 - 1.86) 
1.56 (0.75 - 3.26) 
 
0.89 (0.43 - 1.85) 
1.58 (0.75 - 3.32) 
                *Charlson score: 0=low; 1-2: medium; 3+=high 
PPI:= Proton pump inhibitors; H2RA: = H2-receptor antagonist 
 
 
